Autonomix Reports Preliminary Results From Clinical Trial Of RF Ablation Technology, Showing 100% Of Responder Group Eliminated Opioid Use And Reduced Pain Scores
Portfolio Pulse from Benzinga Newsdesk
Autonomix has reported preliminary results from its clinical trial of RF ablation technology, showing significant success in eliminating opioid use and reducing pain scores among the responder group. The trial is expected to complete enrollment by the end of 2024.
October 28, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autonomix's RF ablation technology shows promising preliminary results in a clinical trial, with 100% of the responder group eliminating opioid use and significantly reducing pain scores. The trial is expected to complete enrollment by the end of 2024.
The preliminary results indicate a strong positive outcome for Autonomix's RF ablation technology, which could lead to increased investor confidence and a potential rise in stock price. The elimination of opioid use and significant pain reduction are critical factors in the healthcare sector, making this development particularly impactful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100